Effects of Vitamin K$_2$ on the Development of Osteopenia in Rats as the Models of Osteoporosis

Jun Iwamoto,$^1$ Tsuyoshi Takeda,$^1$ and Yoshihiro Sato$^2$

$^1$Department of Sports Medicine, Keio University School of Medicine, Tokyo, Japan; $^2$Department of Neurology, Mitate Hospital, Fukuoka, Japan.

Vitamin K$_2$ is widely used for the treatment of osteoporosis in Japan. To understand the effects of vitamin K$_2$ on bone mass and bone metabolism, we reviewed its effects on the development of osteopenia in rats, which characterizes models of osteoporosis. Vitamin K$_2$ was found to attenuate the increase in bone resorption and/or maintain bone formation, reduce bone loss, protect against the loss of trabecular bone mass and its connectivity, and prevent the decrease in strength of the long bone in ovariectomized rats. However, combined treatment of bisphosphonates and vitamin K$_2$ had an additive effect in preventing the deterioration of the trabecular bone architecture in ovariectomized rats, while the combined treatment of raloxifene and vitamin K$_2$ improved the bone strength of the femoral neck. The use of vitamin K$_2$ alone suppressed the increase in trabecular bone turnover and endocortical bone resorption, which attenuated the development of cancellous and cortical osteopenia in orchidectomized rats. In addition, vitamin K$_2$ inhibited the decrease in bone formation in prednisolone-treated rats, thereby preventing cancellous and cortical osteopenia. In sciatic neurectomized rats, vitamin K$_2$ suppressed endocortical bone resorption and stimulated bone formation, delaying the reduction of the trabecular thickness and retarding the development of cortical osteopenia. Vitamin K$_2$ also prevented the acceleration of bone resorption and the reduction in bone formation in tail-suspended rats, which counteracted cancellous bone loss. Concomitant use of vitamin K$_2$ with a bisphosphonate ameliorated the suppression of bone formation and more effectively prevented cancellous bone loss in tail-suspended rats. Vitamin K$_2$ stimulated renal calcium reabsorption, retarded the increase in serum parathyroid hormone levels, and attenuated cortical bone loss primarily by suppressing bone resorption in calcium-deficient rats while maintaining the strength of the long bone in rats with magnesium deficiency. These findings suggest that vitamin K$_2$ may not only stimulate bone formation, but may also suppress bone resorption. Thus, vitamin K$_2$ could regulate bone metabolism in rats, which represented the various models of osteoporosis. However, the effects of vitamin K$_2$ on bone mass and bone metabolism seem to be modest.

Key Words: Vitamin K$_2$, bone formation, bone resorption, rat, osteopenia

INTRODUCTION

Vitamin K$_2$ is widely used for the treatment of osteoporosis in Japan. The up-regulation in the expression of bone markers in vivo suggests the anabolic action of vitamin K$_2$. Vitamin K$_2$ is known to be a cofactor of γ-carboxylase, which converts the glutamic acid (Glu) residue in osteocalcin molecules to γ-carboxyglutamic acid (Gla) and is, therefore, essential for γ-carboxylation of osteocalcin. Vitamin K$_2$ is known to be a cofactor of γ-carboxylase, which converts the glutamic acid (Glu) residue in osteocalcin molecules to γ-carboxyglutamic acid (Gla) and is, therefore, essential for γ-carboxylation of osteocalcin. Thus, the role of vitamin K$_2$ in bone formation was thought to be as an essential cofactor for the γ-carboxylation of osteocalcin. However, recent evidence suggests that vitamin K$_2$ also has a transcriptional regulatory function. Vitamin K$_2$ is a transcriptional regulator of bone-specific genes that acts through steroid and xenobiotic receptors (SXR) to favor the expression of osteoblastic markers. Thus, the role of vitamin K$_2$ in the regulation of bone formation may be in the γ-carboxylation of osteocalcin and the mediation of osteoblastic marker expression through the use of SXR, although the exact mechanism remains uncertain. Therefore, the effects of vitamin K$_2$ on bone formation are of interest in the treatment of osteoporosis.

However, vitamin K$_2$ has also been reported to

Received February 23, 2005
Accepted June 1, 2005
Reprint address: requests to Dr. Jun Iwamoto, Department of Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: 81-3-3353-1211, Fax: 81-3-3352-9467, E-mail: jiwamoto@sc.itc.keio.ac.jp
inhibit the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation. In addition, vitamin K$_2$ has induced osteoclast apoptosis in unfractionated bone cells and isolated osteoclasts on dentine slices, suggesting that the inhibitory effect of vitamin K$_2$ on osteoclastic bone resorption may be exerted via targeting osteoclasts for apoptosis. It has also been suggested that the inhibitory effect of vitamin K$_2$ on bone resorption may be independent of the γ-carboxylation system, but related to its side chain. This line of evidence is substantiated by the anti-resorptive effect of vitamin K$_2$ on bone in vitro.

Clinically, vitamin K$_2$ sustains the lumbar bone mineral density (BMD) and prevents osteoporotic fractures in patients with postmenopausal osteoporosis, prevents the loss of the lumbar BMD partly by inhibiting the reduction in osteoprotegerin (OPG) and reduces the incidence of vertebral fractures in patients with glucocorticoid-induced osteoporosis, increases the metacarpal BMD in the paralytic upper extremities of patients with cerebrovascular disease or in elderly women with Parkinson's disease, reduces the incidence of nonvertebral fractures in elderly women with Alzheimer's disease when treated with both vitamin D$_2$ and calcium supplements, and sustains the lumbar BMD in patients with liver-dysfunction-induced osteoporosis. Furthermore, vitamin K deficiency, which is characterized by an increased circulating level of undercarboxylated osteocalcin and, subsequently, reduced production of γ-carboxylated osteocalcin, may also contribute to the risk of osteoporotic fractures. Although its effect on BMD may be quite modest, vitamin K$_2$ may have the potential to regulate bone metabolism and reduce the risk of osteoporotic fractures. Thus, vitamin K$_2$ may be useful for treating the various types of osteoporosis by regulating bone formation and resorption. Although it has been recognized that vitamin K$_2$ increases the serum osteocalcin levels, its effect on bone resorption seems to be less certain. To understand the effects of vitamin K$_2$ on bone mass and bone metabolism, we reviewed its effects on the development of osteopenia in rats, the model of osteoporosis.

**EFFECTS OF VITAMIN K$_2$ ON THE DEVELOPMENT OF OSTEOPENIA IN RATS**

**Effects of vitamin K$_2$ in ovariectomized rats**

Treatment with vitamin K$_2$ alone

Estrogen deficiency, caused by ovariectomy in rats, resulted in bone loss due to increased bone turnover. Several studies have shown the beneficial effects of vitamin K$_2$ on bone loss in ovariectomized rats. Some studies showed that vitamin K$_2$ prevented early bone loss of the femoral BMD through the inhibition of bone resorption, attenuated the increase in osteoclastic bone resorption, maintained the accelerated osteoblastic activity in the femoral metaphysis, protected against the loss of trabecular bone mass and its connectivity in the proximal tibial metaphysis (Fig. 1), reduced mineralized bone loss in the lumbar vertebra, and prevented the decrease in the bone strength of the femoral diaphysis in ovariectomized rats. However, other studies, performed by Binkley et al. and Otomo et al., showed that vitamin K$_2$ did not reduce ovariectomy-associated elevation of bone turnover and that vitamin K$_2$ did not reduce the distal femoral BMD, bone mass/density, structure, mineral properties (mineral-to-matrix ratio), or the bone strength of the lumbar vertebra and femur. Thus, because of the modest effects of vitamin K$_2$ on the bone mass and/or bone metabolism, its effects on bone loss, formation, and resorption in ovariectomized rats remain controversial. However,

**Fig. 1.** Three-dimensional μCT images of the proximal tibial metaphysis in rats [Adopted from the reference 31]. The upper row shows the whole bone and the lower row shows the same specimens after the removal of the cortex. Vitamin K$_2$ prevented O VX-induced cancellous bone loss. O VX, ovariectomy; Sham, sham-operation; MK-4, menaquinone-4 (menatetrenone: vitamin K$_3$).
vitamin K₂ may have the potential to regulate bone metabolism, maintain bone strength or trabecular bone architecture, and at least attenuate bone loss in ovariectomized rats.

**Combined treatment with vitamin K₂ and vitamin D₃**

A few studies have demonstrated a preventative effect of this combined treatment on bone loss in ovariectomized rats. Matsunaga et al. (Fig. 2). Miyata 
and Hara et al. demonstrated that the combined treatment of 1α-hydroxyvitamin D₃ and vitamin K₂ was more effective for treating bone mass loss in the proximal tibial metaphysis and/or the bone strength of the femoral diaphysis in ovariectomized rats. Although these studies did not clarify the mechanism underlying the beneficial effects of this combined treatment on ovariectomy-induced bone loss, these results illustrated the treatment's additive effect on osteopenia in ovariectomized rats.

**Combined treatment with vitamin K₂ and bisphosphonates**

A few studies have examined the effects of the combined treatment of vitamin K₂ and bisphosphonates on osteopenia that was induced by ovariectomy. Ito clearly demonstrated that risedronate prevented the deterioration in the connectivity of the trabeculae in the proximal tibial metaphysis in ovariectomized rats, whereas vitamin K₂ increased the trabecular thickness. Thus, the combined treatment of risedronate and vitamin K₂ had an additive effect in preventing the deterioration of the trabecular bone architecture in ovariectomized rats.

**Combined treatment with vitamin K₂ and raloxifene**

Iwamoto et al. demonstrated the skeletal effects of the combined treatment of vitamin K₂ and raloxifene in ovariectomized rats. Vitamin K₂ alone increased bone formation, whereas raloxifene alone and in combination with vitamin K₂ reduced bone turnover. Raloxifene alone, but not vitamin K₂ alone, prevented ovariectomy-induced bone loss in the distal femoral metaphysis and proximal tibial metaphysis, as did the vitamin K₂ plus raloxifene combination. No significant beneficial effect of either raloxifene or vitamin K₂ alone was observed on the femoral neck bone strength; however, vitamin K₂ plus raloxifene had greater femoral neck bone strength than the sham-operated controls (Fig. 3). Thus, raloxifene and vitamin K₂ had complementary effects on bone resorption and formation activities, respectively, resulting in a significant improvement in the femoral neck bone strength.

**Effects of vitamin K₂ in orchidectomized rats**

Testosterone in males is important for skeletal growth during the period of linear growth and is
responsible for the maintenance of skeletal mass at a later stage of life.\textsuperscript{40-42} Testosterone deficiency, induced by orchidectomy in rats, induced high-turnover cancellous osteopenia\textsuperscript{43} and cortical osteopenia with cortical porosity and decreased periosteal bone formation.\textsuperscript{44} A few studies have reported the beneficial effects of vitamin K\textsubscript{2} on the cancellous and cortical bone mass in orchidectomized rats. Iwamoto et al.\textsuperscript{45} showed that orchidectomy in rats induced cancellous and cortical osteopenia by increasing trabecular and endocortical bone turnover in the proximal tibial metaphysis. They also showed that vitamin K\textsubscript{2} administration in orchidectomized rats suppressed trabecular bone turnover and endocortical bone resorption, attenuating the development of cancellous and cortical osteopenia. This effect of vitamin K\textsubscript{2} on cancellous osteopenia was primarily mediated by its attenuation of the reduction of the trabecular thickness in these rats. These results suggest that vitamin K\textsubscript{2} may have the potential to suppress bone resorption or bone turnover, attenuating cancellous and cortical bone loss in orchidectomized rats.

**Effects of vitamin K\textsubscript{2} in glucocorticoid-treated rats**

Glucocorticoid treatment decreased bone formation, which resulted in cortical and cancellous osteopenia in rats.\textsuperscript{46} A few studies have reported the effects of vitamin K\textsubscript{2} on the cancellous and cortical bones in prednisolone-treated rats. Hara et al.\textsuperscript{47} reported that prednisolone treatment in rats reduced the tibial length, dry weight, bone density, femoral length, bone strength, and calcium content, but vitamin K\textsubscript{2} improved these reductions. Hara et al.\textsuperscript{46} also reported that prednisolone treatment decreased bone formation, resulting in cancellous and cortical osteopenia in the tibia, and that vitamin K\textsubscript{2} inhibited the decrease in bone formation, thereby preventing cancellous and cortical osteopenia (Fig. 4 and 5). The results of this study suggest that vitamin K\textsubscript{2} may have the potential to prevent bone loss by preventing the decrease in bone formation, as noted in rats treated with glucocorticoid.

**Effects of vitamin K\textsubscript{2} in sciatic neurectomized rats**

Hind-limb immobilization by sciatic neurectomy increased bone resorption and decreased bone formation, resulting in cancellous and cortical osteopenia in the hind-limb of rats.\textsuperscript{45,48,49} Several studies have reported the effects of vitamin K\textsubscript{2} on the cancellous and/or cortical bone mass in sciatic neurectomized rats. Iwasaki et al.\textsuperscript{48} showed that sciatic neurectomy in rats induced cancellous and cortical osteopenia by increasing trabecular and endocortical bone turnover in the proximal tibial metaphysis. They also showed that vitamin K\textsubscript{2} administration in sciatic neurectomized rats suppressed trabecular bone turnover and endocortical bone resorption, attenuating the development of cancellous and cortical osteopenia. Iwasaki-Ishizuka et al.\textsuperscript{49} also showed that sciatic neurectomy in rats was associated with a transient increase in bone resorption and a sustained reduction in bone.
formation, resulting in a reduction in the BMD of the femoral distal metaphysis and diaphysis and also a reduction in the bone strength of the femoral diaphysis, and that vitamin K₂ ameliorated these abnormalities. Iwamoto et al. showed that sciatic neurectomy in rats increased bone resorption and decreased bone formation in the cancellous bone. They also showed a decrease in periosteal bone formation and an increase in endocortical bone turnover in the cortical bone, resulting in cancellous and cortical osteopenia in the tibia. Vitamin K₂ administration in sciatic neurecto-

Fig. 4. Three-dimensional μCT images of the proximal tibial metaphysis in rats [Adopted from the reference 46]. The lower row shows the whole bone and the upper row shows the same specimens after the removal of the cortex. Vitamin K₂ administration prevented cancellous bone loss that was induced by 3 and 30 mg/kg Pred-treatment. Pred, prednisolone.

Fig. 5. Micrographs of the cross-sections of the cortical bone of the tibial diaphysis in rats (magnification ×400) [Adopted from the reference 46]. The tibial diaphysis was fixed with 70% alcohol and embedded in methylmethacrylate after Villanueva bone staining. It was sectioned transversely (10 μm thickness) at a point 2.78 mm from the tibiofibular junction. Images were scanned by fluorescence laser microscope. The red lines indicate the cortical periosteal surface, the green lines indicate calcein that was taken into the bone formation area, and the distance between the double green lines indicates bone formation width during the 7 day period. Vitamin K₂ administration prevented the decrease in periosteal bone formation that was induced by 3 and 30 mg/kg Pred-treatment. Pred: prednisolone.
mized rats suppressed endocortical bone resorption and stimulated bone formation and attenuated the reduction of the trabecular thickness, without any significant effect on the cancellous bone mass, retarding the development of cortical osteopenia in the tibia. These results suggest that vitamin K₂ has the potential to suppress bone resorption or bone turnover and/or stimulate bone formation, attenuating cancellous and cortical bone loss in the hind-limb of sciatic neurectomized rats.

Furthermore, Iwasaki-Ishizaka et al. demonstrated that vitamin K₂ increased the BMD of the distal femoral metaphysis by increasing bone formation and decreasing bone resorption in rats with sciatic neurectomy induced-bone loss. In addition, vitamin K₂ increased γ-carboxylated osteocalcin levels and decreased undercarboxylated osteocalcin levels in the serum. These results suggest that vitamin K₂ improves osteopenia by improving osteoblast dysfunction and accelerating γ-carboxylation of osteocalcin in sciatic neurectomized osteopenic rats.

Effects of vitamin K₂ in tail-suspended rats

Treatment with vitamin K₂ alone

Tail-suspension increased bone resorption and decreased bone formation in the cancellous bone and/or decreased bone formation in the cortical bone, resulting in cancellous and cortical osteopenia in the hind-limb of rats. In particular, suppression of bone formation seemed to play a more important role than the acceleration of bone resorption. Iwasaki et al. reported that vitamin K₂ prevented the acceleration of bone resorption and the reduction in bone formation in the tibia of tail-suspended rats, counteracting the loss of the BMD or cancellous bone mass. Thus, vitamin K₂ has the potential to suppress bone resorption and/or stimulate bone formation, attenuating cancellous bone loss in the hind-limb of tail-suspended rats.

Combined treatment with vitamin K₂ and bisphosphonates

Iwasaki et al. demonstrated that incadronate attenuated cancellous bone loss, by a marked suppression of bone turnover in the proximal tibial metaphysis of tail-suspended rats, and that the combination of incadronate and vitamin K₂ led to further attenuation of cancellous bone loss by increasing bone formation, when compared to incadronate alone (Fig. 6). These findings suggest that the concomitant use of vitamin K₂ with bisphosphonates ameliorated the suppression of bone formation, which efficiently prevented cancellous bone loss in the hind-limb of tail-suspended rats.

Effects of vitamin K₂ in rats with calcium-deficiency

Severe calcium imbalance reduces bone mass in rats. Several studies have reported the beneficial effects of vitamin K₂ on osteopenia and calcium balance in calcium-deficient rats. Kato et al. reported that a calcium-deficient-diet (low 0.08-0.1% vs. normal 0.8-1.2%) reduced the femoral BMD in rats by 12% and that vitamin K₂ reversed calcium-deficiency-induced BMD loss. Iwamoto et al. demonstrated...
reported that calcium deficiency (low-calcium diet: low 0.1% vs. normal 0.5%) in rats induced hypocalcemia, increased the serum parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D levels, decreased the serum 25-hydroxyvitamin D levels, and stimulated intestinal calcium absorption and renal calcium reabsorption. Calcium deficiency also reduced the cortical bone mass of the tibial diaphysis with decreased periosteal bone gain and an enlarged marrow cavity. Vitamin K2 stimulated renal calcium reabsorption and retarded the increase in the serum PTH levels in calcium-deficient rats. However, since there was no significant change in the serum 1,25-dihydroxyvitamin D levels, vitamin K2 did not appear to have influenced intestinal calcium absorption. Vitamin K2 also retarded cortical bone loss of the tibial diaphysis, primarily by suppressing bone resorption. Robert et al. showed that vitamin K deficiency in rats induced hypercalciuria, but did not change the intestinal calcium absorption, and that vitamin K supplementation in vitamin K-deficient rats corrected hypercalciuria.

Kobayashi et al. demonstrated that severe calcium/magnesium-deficiency (low-calcium and magnesium diet: low-calcium 0.01% vs. normal 0.5%; low-magnesium 0.003% vs. normal 0.01%) decreased the serum calcium and magnesium levels, as well as the cortical bone mass of the femur, but increased the serum PTH levels and renal calcium excretion. Vitamin K2 attenuated the abnormal decrease in the serum calcium and magnesium levels and the abnormal increase in the serum PTH levels and renal calcium excretion in severe calcium/magnesium-deficient rats.

Kobayashi et al. also reported that ovariectomy in rats altered calcium balance, resulting in the decrease in the BMD and the cortical bone mass of the femoral diaphysis. They further noted that vitamin K2 supplementation in ovariectomized rats improved calcium balance and prevented reduction of the cortical bone mass. These findings suggest that vitamin K2 may have the potential to improve calcium balance, particularly renal calcium reabsorption, and to attenuate cortical bone loss in calcium-deficient rats.

Effects of vitamin K2 in rats with magnesium deficiency

Magnesium deficiency reduces bone strength without affecting the cortical bone mass in rats. Kobayashi et al. demonstrated that a low-magnesium diet resulted in the reduction of the bone strength of the femoral diaphysis, despite no significant changes in the cortical BMD and cortical thickness. Vitamin K2 also did not affect the cortical BMD or cortical thickness of the femoral diaphysis, but it inhibited a decrease in bone strength. These findings suggest that vitamin K2 may be useful in maintaining bone strength in rats with magnesium deficiency.

CONCLUSION

We reviewed the effects of vitamin K2 on the development of osteopenia in rats, the model of osteoporosis. The rats were either ovariectomized, orchidectomized, sciatic neurectomized, tail-suspended, glucocorticoid-treated, or calcium-or magnesium-deficient. It was found that vitamin K2 could regulate bone metabolism in these rats. However, the novelty of the observations is somewhat incremental because most of the pre-clinical animal studies used high-doses of vitamin K2 to test its pharmacological efficacy for bone. Actually, the effects of vitamin K2 on bone mass and bone metabolism seem to be modest. Therefore, molecular changes in bone metabolism need to be investigated to determine the exact mechanisms by which vitamin K2 regulates homeostasis in bones.

REFERENCES

1. Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003;278:43919-27.
2. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.
3. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 1997;12:431-8.
4. Shearer MJ. Vitamin K. Lancet 1995;345:229-34.

5. Vermeer C, Jie KS, Knapen MH. Role of vitamin K in bone metabolism. Annu Rev Nutr 1995;15:1-22.

6. Takeuchi Y, Suzawa M, Fukumoto S, Fujita T. Vitamin K\textsubscript{2} inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone 2000;27:769-76.

7. Kameda T, Miyazawa K, Mori Y, Yuasa T, Shiokawa M, Nakamaru Y, et al. Vitamin K\textsubscript{2} inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun 1996;220:515-9.

8. Notoya K, Yoshida K, Shirakawa Y, Taketomi S, Tsuda M. Similarities and differences between the effects of ipriflavone and vitamin K on bone resorption and formation in vitro. Bone 1995;16 Suppl:349S-53S.

9. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K\textsubscript{2} (menatetrenone) on bone resorption may be related to its side chain. Bone 1995;16:179-84.

10. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K\textsubscript{2} (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-21.

11. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfalcacidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Study. Am J Med 2004;117:549-55.

12. Iwamoto J, Takeda T, Ichimura S. Combined treatment with vitamin K\textsubscript{2} and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 2003;44:751-6.

13. Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, et al. Vitamin K\textsubscript{2} inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 2005;23:41-7.

14. Tanaka I, Oshima K. Prevention of vertebral fractures with therapeutic agents in corticosteroid-induced osteoporosis. Osteoporosis Japan 2002;10:244-7 (in Japanese).

15. Tanaka I, Oshima K. Effects of menatrenone, a vitamin K analog, on prevention of vertebral fracture in corticosteroid-induced osteoporosis. J Bone Miner Res 2001;16 Suppl 1:S35S1.

16. Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K\textsubscript{2} (menatrenone) treatment in children treated with glucocorticoid and alfalcacidol. Endocr J 2001;48:11-8.

17. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000;66:123-8.

18. Sakai N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, et al. Vitamin K\textsubscript{2} inhibits glucocorticoid-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000;66:123-8.

19. Sato Y, Honda Y, Kuno H, Oizumi K. Menatrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23:291-6.

20. Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, et al. Amelioration of osteoporosis by menatrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 2002;31:114-8.

21. Sato Y, Kanoko T, Satoh K, Iwamoto J. Menatrenone and vitamin D\textsubscript{2} with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer’s disease. Bone 2005;36:61-8.

22. Shiomi S, Nishiguchi S, Kubo S, Tamori A, Habu D, Takeda T, et al. Vitamin K\textsubscript{2} (menatrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 2002;97:978-81.

23. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993;91:1769-74.

24. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996;18:487-8.

25. Vergnoud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997;82:719-24.

26. Luukinen H, Kakonen SM, Pettersson K, Koski K, Laippala P, Lovgren T, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000;15:2473-8.

27. Feskanch D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999;69:74-9.

28. Sato Y, Honda Y, Hayashida N, Iwamoto J, Kanoko T, Satoh K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer’s disease. Arch Phys Med Rehabil 2005;86:576-81.

29. Akiyama Y, Hara K, Kobayashi M, Tomiuga T, Nakamura T. Inhibitory effect of vitamin K\textsubscript{2} (menatrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy X-ray absorptiometric study. Jpn J Pharmacol 1999;80:67-74.

30. Asawa Y, Amizuka N, Hara K, Kobayashi M, Aita M, Li M, et al. Histochemical evaluation for the biological effect of menatrenone on metaphyseal trabeculae of ovariectomized rats. Bone 2004;35:870-80.

31. Mawatari T, Miura H, Higaki H, Moro-Oka T, Kurata K, Murakami T, et al. Effect of vitamin K\textsubscript{2} on three-dimensional trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 2000;15:1810-7.

32. Xin F, Takemitsu M, Atsuta Y. Effect of vitamin K\textsubscript{2} on chronic glomerulonephritis. Calcif Tissue Int 2000;6:123-8.
lumbar vertebral bone: histomorphometric analyses in experimental osteoporotic rats. J Orthop Sci 2001;6:535-9.
33. Shiraiishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, et al. A comparison of alfalcacidol and menatetrenone for the treatment of bone loss on an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002;71:69-79.
34. Binkley N, Krueger D, Engelke J, Crenshaw T, Suttie J. Vitamin K supplementation does not affect ovariectomy-induced bone loss in rats. Bone 2002;30:897-900.
35. Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Philp RJ, et al. Regulation of mineral-to-matrix ration of lumbar trabecular bone in ovariectomized rats treated with risendronate in combination with or without vitamin K3. J Bone Miner Metab 2004;22:404-14.
36. Matsunaga S, Ito H, Sakou T. The effect of vitamin K and D supplementation on ovariectomy-induced bone loss. Calcif Tissue Int 1999;65:285-9.
37. Hara K, Kobayashi M, Akiyama Y. Effect of combined treatment with vitamin K2 and 1α-(OH)-vitamin D3 on bone loss in ovariectomized rats. Foila Pharmacol Jpn 2001;118:231-40 (in Japanese).
38. Ito M. Bone mass, microstructure, and quality with bone strength-The effects of antiresorptive agents. J Jpn Soc Bone Morphom 2002;12:51-4 (in Japanese).
39. Iwamoto J, Yeh JK, Schmidt A, Rowley E, Stanfield L, Takeda T, et al. Raloxifene and vitamin K3 combination use for the treatment of bone loss on an ovariectomized rat model of osteoporosis. J Orthop Sci 2002;7:379-85.
40. Bertelloni S, Baroncelli GI, Battini R, Perri G, Saggese G. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res 1995;10:1488-95.
41. Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 1997;82:658-65.
42. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
43. Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: A sequential histomorphometric study. J Bone Miner Res 2000;15:1085-98.
44. Prakasham G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchidectomized rats. Bone 1999;24:491-7.
45. Iwamoto J, Yeh JK, Takeda T. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res 2003;18:776-83.
46. Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 2002;31:575-81.
47. Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone 1993;14:813-8.
48. Iwasaki Y, Yamato H, Murayama H, Takahashi T, Ezawa I, Kurokawa K, et al. Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Jpn J Pharmacol 2002;90:88-93.
49. Iwasaki-Ishizuka Y, Yamato H, Murayama H, Abe M, Takahashi K, Kurokawa K, et al. Menatetrenone ameliorates reduction in bone mineral density and bone strength in sciatic neurectomized rats. J Nutr Sci Vitaminol 2003;49:256-61.
50. Iwasaki-Ishizuka Y, Yamato H, Murayama H, Ezawa I, Kurokawa K, Fukagawa M. Menatetrenone rescues bone loss by improving osteoblast dysfunction in rats immobilized by sciatic neurectomy. Life Sci 2005;76:1721-34.
51. Kodama Y, Nakayama K, Fuse H, Fukumoto S, Nawahara H, Takahashi H, et al. Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 1997;12:1058-67.
52. Moriyama I, Iwamoto J, Takeda T, Toyama Y. Comparative effects of intermittent administration of human parathyroid hormone (1-34) on cancellous and cortical bone loss in tail-suspended and sciatic neurectomized young rats. J Orthop Sci 2002;7:379-85.
53. Iwasaki Y, Yamato H, Murayama H, Sato M, Takahashi T, Ezawa I, et al. Maintenance of trabecular structure and bone volume by vitamin K3 in mature rats with long-term tail suspension. J Bone Miner Metab 2002;20:216-22.
54. Morey ER, Baylink DJ. Inhibition of bone formation during space flight. Science 1978;201:1138-41.
55. Iwasaki Y, Yamato H, Murayama H, Sato M, Takahashi T, Ezawa I, et al. Combination use of vitamin K2 further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension rats. J Bone Miner Metab 2003;21:154-60.
56. Kato S, Mano T, Kobayashi T, Yamazaki N, Himeno Y, Yamamoto K, et al. A calcium-deficient diet caused decreased bone mineral density and secondary elevation of estrogen in aged male rats-effect of menatetrenone and elcatonin. Metabolism 2002;51:1250-4.
57. Iwamoto J, Yeh JK, Takeda T, Ichimura S, Sato Y. Comparative effect of vitamin K and vitamin D supplementation on prevention of osteopenia in calcium-deficient young rats. Bone 2003;33:557-66.
58. Robert D, Jorgetti V, Lacour B, Leclerq M, Cournot-Yonnette C, Robert D, et al. Hypercalcemia during experimental vitamin K deficiency in the rat. Calcif Tissue Int 1985;37:143-7.
59. Kobayashi M, Hara K, Akiyama Y. Effect of menatetrenone (Vitamin K3) on bone mineral density and bone strength in Ca/Mg deficient rats. Nippon Yakurigaku Zasshi 2002;120:195-204 (in Japanese).
60. Kobayashi M, Hara K, Akiyama Y. Effects of vitamin
K$_2$ (menatetrenone) on calcium balance in ovariecto-
mized rats. Jpn J Pharmacol 2002;88:55-61.

61. Kobayashi M, Hara K, Akiyama Y. Effects of vitamin
K$_2$ (menatetrenone) and alendronate on bone mineral
density and bone strength in rats fed a low-magnesium
diet. Bone 2004;35:1136-43.